8 completed, 5 terminated, 1 withdrawn. 14 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 8, Terminated 5, Withdrawn 1 |
| Phase 2 | 9 | Terminated 5, Completed 3, Withdrawn 1 |
Follow Stem Cell Infusion: new trials by email Literature Review of Stem Cell Infusion trials Research Report on Stem Cell Infusion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Siplizumab for Sickle Cell Disease Transplant Siplizumab, Exchange Transfusion, Total Body Irradiation - Anemia, Sickle Cell | Phase 1 / Phase 2 | Terminated | Columbia University | 1 | 2023-09-28 | 2026-06-10 |
| URMC Related Haplo-identical Donor BMT Total Body Irradiation 1200 cGy, Fludarabine, Pre-Stem Cell Infusion Cyclophosphamide - Hematological Disease, Immune Deficiencies | Phase 1 | Completed | University of Rochester | 74 | 2015-10-01 | 2021-11-03 |
| Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene Fludarabine, Melphalan, Alemtuzumab - Leukemia, Myeloma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 3 | 2013-12-27 | 2019-07-16 |
| Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin Stem cell infusion - Critical Limb Ischemia (CLI) | Phase 1 / Phase 2 | Terminated | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | 20 | 2011-09-01 | 2018-12-19 |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies Vorinostat, Gemcitabine, Busulfan - Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 78 | 2011-08-01 | 2015-11-18 |
| A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias Natural Killer (NK) Cell Infusion, Stem Cell Infusion - Leukemia, Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2011-01-29 | 2019-08-22 |
| Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant G-CSF, AMD3100, Leukapheresis - Stem Cell Transplant Patients | Phase 1 | Completed | Washington University School of Medicine | 29 | 2010-04-29 | 2017-01-25 |
| Lenalidomide and High-Dose Melphalan Lenalidomide, Melphalan, Stem Cell Infusion - Myeloma, Stem Cell Transplantation | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 61 | 2010-03-01 | 2016-06-06 |
| Safety and Effectiveness of Cord Blood Stem Cell Infusion for the Treatment of Cerebral Palsy in Children Cord Blood Infusion, Intravenous Sham - Cerebral Palsy | Phase 1 / Phase 2 | Withdrawn | Augusta University | 2010-01-01 | 2022-10-07 | |
| Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders Campath -1H, Fludarabine, Anti-CD45 - Severe Combined Immunodeficiency Disease, Severe Primary Immunodeficiency Disorder | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 3 | 2007-10-01 | 2013-07-02 |
| Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies Busulfan, Gemcitabine, Melphalan - Leukemia, Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 145 | 2006-12-01 | 2016-06-03 |
| Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma Y Zevalin, In Zevalin, Rituxan - Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 40 | 2003-09-01 | 2014-09-11 |
| Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases ANTI-CD45, CAMPATH-1H, FK506 - Hematologic Malignancy | Phase 1 / Phase 2 | Completed | Baylor College of Medicine | 24 | 2002-11-01 | 2012-06-29 |
| Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia CAMPATH-1H, Anti-CD45, Fludarabine - Fanconi Anemia, Severe Aplastic Anemia | Phase 1 / Phase 2 | Terminated | Baylor College of Medicine | 5 | 2001-07-01 | 2018-05-24 |
Lymphoma (6) · Hodgkin Disease (4) · Multiple Myeloma (4) · Leukemia (3) · Lymphoma, Non-Hodgkin (3) · Neoplasms, Plasma Cell (3) · Anemia, Aplastic (2) · Hematologic Neoplasms (2) · Myelodysplastic Syndromes (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia, Sickle Cell (1) · Cerebral Palsy (1) · Chronic Limb-Threatening Ischemia (1) · Disease (1) · Fanconi Anemia (1)
M.D. Anderson Cancer Center (5) · Baylor College of Medicine (3) · Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (1) · Augusta University (1) · Columbia University (1) · National Cancer Institute (NCI) (1) · University of Rochester (1) · Washington University School of Medicine (1)
United States (13) · Spain (1)
Bernat Soria (1) · Issa F. Khouri, MD,BS (1) · James E Carroll, M.D. (1) · Jeffrey Andolina, MD (1) · John DiPersio, M.D., Ph.D. (1) · Malcolm Brenner, M.B., Ph.D., (1) · Malcolm Brenner, MD (1) · Malcolm K Brenner, MD (1) · Markus Y Mapara, MD, PhD (1) · Muzaffar H. Qazilbash, MD (1) · Nirali N Shah, M.D. (1) · Richard E. Champlin, MD, BS (1) · Robert Krance, MD (1) · Yago Nieto, MD, PhD (1) · Yago Nieto, MD,PHD (1)
PMID 25452614, PMID 26071868, PMID 29476021, PMID 30826465, PMID 33951890